Dangerous deception--hiding the evidence of adverse drug effects

Affiliations

Free article

Comment

Jerry Avorn. N Engl J Med. 2006.

Free article

. 2006 Nov 23;355(21):2169-71.

doi: 10.1056/NEJMp068246.

¹ Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston, USA.

No abstract available

Comment on

The risk associated with aprotinin in cardiac surgery.
Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mangano DT, et al. N Engl J Med. 2006 Jan 26;354(4):353-65. doi: 10.1056/NEJMoa051379. N Engl J Med. 2006. PMID: 16436767
Observational studies of drug safety--aprotinin and the absence of transparency.
Hiatt WR. Hiatt WR. N Engl J Med. 2006 Nov 23;355(21):2171-3. doi: 10.1056/NEJMp068252. N Engl J Med. 2006. PMID: 17124013 No abstract available.